Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

Por Arcaini, Luca, Lamy, Thierry, Walewski, Jan, Belada, David, Mayer, Jiri, Radford, John, Jurczak, Wojciech, Morschhauser, Franck, Alexeeva, Julia, Rule, Simon, Cabeçadas, José, Campo, Elias, Pileri, Stefano A., Biyukov, Tsvetan, Patturajan, Meera, Casadebaig Bravo, Marie‐Laure, Trnĕný, Marek
Publicado no Br J Haematol (2017)